MedTrace Logo

Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried

NCT07357545 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2040

Last updated 2026-01-22

No results posted yet for this study

Summary

To evaluate the immunogenicity and safety of different post-exposure prophylaxis (PEP) schedules of Sinovac rabies vaccine, in comparison with a marked rabies vaccinein china, in subjects aged 10-60 years old.

Conditions

  • Rabies (Healthy Volunteers)

Interventions

BIOLOGICAL

Sinovac rabies vaccine

Rabies Vaccine (Serum-free Vero Cell), Freeze-dried using three types of PEP schedules

BIOLOGICAL

Marketed rabies vaccine

A markted Rabies Vaccine using 5 doses of PEP schedules

Sponsors & Collaborators

  • Sinovac Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-27
Primary Completion
2022-09-21
Completion
2023-06-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07357545 on ClinicalTrials.gov